MHB088C not checked
Qilu Pharmaceutical · QLC5508
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle”In the company’s words, NCT06954246 on ClinicalTrials.gov
- Tested for
- Small Cell Lung Cancer Extensive Stage, Esophageal Squamous Cell Carcinoma (ESCC), Prostate Cancer, Extensive-stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Advanced/Metastatic Solid Tumors, Advanced Solid Tumor, Advanced Prostate Cancer and 2 more
- Main trialPhase 3
- “This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).”In the company’s words, NCT06954246 on ClinicalTrials.gov
- Other names
- QLC5508
Other drugs for Small Cell Lung Cancer Extensive Stage
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up8
- 5 DecPhase 1 trial completes · ClinicalTrials.gov
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- May 2027Phase 3 trial completes · ClinicalTrials.gov
- 5 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 20 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
- 26 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
- Aug 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2027 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | |
| Phase 3Recruiting | 5 Jun 2028 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | |
| Phase 3Not yet recruiting | 20 Jun 2028 | QLC5508 in Participants With Metastatic Prostate Cancer | |
| Phase 3Recruiting | 15 Mar 2029 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | |
| Phase 3Not yet recruiting | 26 Mar 2029 | QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma | |
| Phase 1/2Recruiting | Jul 2026 | Study of MHB088C for Patients With Advanced Solid Malignant Tumors | |
| Phase 1/2Recruiting | Oct 2026 | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | |
| Phase 1/2Recruiting | Dec 2026 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | |
| Phase 1/2Recruiting | Aug 2029 | A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors | |
| Phase 1Recruiting | 5 Dec 2026 | Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction | |
| Phase 1/2Unknown | 31 Jan 2026 | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026